| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/18/2001 | US6290957 Anti-IgE antibodies and method of improving polypeptides |
| 09/18/2001 | US6290955 Antibodies against T cells as therapeutics |
| 09/18/2001 | US6290950 Mycosis vaccines |
| 09/18/2001 | US6290712 Laser/sensitizer assisted immunotherapy |
| 09/18/2001 | CA2238879C Thereapeutic applications for the anti-t-bam (cd40-l) monoclonal antibody 5c8 |
| 09/18/2001 | CA2145182C Dna encoding human alpha 1 adrenergic receptors and uses thereof |
| 09/18/2001 | CA2023894C Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulins |
| 09/15/2001 | WO2001068859A2 Il-17 receptor like molecules and uses thereof |
| 09/15/2001 | WO2001066747A2 Proteins named fctrx and nucleic acids encoding same |
| 09/15/2001 | CA2403370A1 Il-17 receptor like molecules and uses thereof |
| 09/15/2001 | CA2401552A1 Proteins named fctrx and nucleic acids encoding same |
| 09/13/2001 | WO2001066778A2 Production of foreign polypeptides in plants as viral coat protein fusions |
| 09/13/2001 | WO2001066776A2 Novel l-form bacterial strains, method for producing same and the use thereof for producing gene products |
| 09/13/2001 | WO2001066754A1 Human antibodies against eotaxin and their use |
| 09/13/2001 | WO2001066751A2 G protein-coupled receptors |
| 09/13/2001 | WO2001066746A2 G-protein coupled receptor related polypeptides |
| 09/13/2001 | WO2001066741A2 Kcnb: a novel potassium channel protein |
| 09/13/2001 | WO2001066716A1 Polypeptide having phosphodiesterase activity |
| 09/13/2001 | WO2001066700A1 Transcutaneous immunization for large particulate antigens |
| 09/13/2001 | WO2001066691A2 Rickettsia felis outer membrane protein |
| 09/13/2001 | WO2001066597A2 Inflammation-related gene |
| 09/13/2001 | WO2001066595A2 Human fgf-23 gene and gene expression products |
| 09/13/2001 | WO2001066572A2 Polynucleotides isolated from e. coli of nature b2/d+ a-, and uses thereof |
| 09/13/2001 | WO2001066571A1 Therapeutic and prophylactic agents derived from aeromonas hydrophila bacterial surface proteins |
| 09/13/2001 | WO2001066569A1 Viral antigen and vaccine against isav (infectious salmon anaemia virus) |
| 09/13/2001 | WO2001066149A2 Nucleic acid formulations for gene delivery and methods of use |
| 09/13/2001 | WO2001066140A1 Use of tgf-beta antagonists to treat or to prevent loss of renal function |
| 09/13/2001 | WO2001066139A1 Use of a compound that selectively binds to cd123 to impair hematologic cancer progenitor cell |
| 09/13/2001 | WO2001066138A2 Dna vaccines against poxviruses |
| 09/13/2001 | WO2001066137A1 Adenovirus formulations |
| 09/13/2001 | WO2001066136A2 Microbial delivery system |
| 09/13/2001 | WO2001066126A1 Sialoadhesin factor-2 antibodies |
| 09/13/2001 | WO2001066124A2 Composition for the treatment of heart failure |
| 09/13/2001 | WO2001066107A2 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases |
| 09/13/2001 | WO2001066085A2 Micellar pharmaceutical compositions for buccal and pulmonary application |
| 09/13/2001 | WO2001065934A2 Applications of immune system tolerance to treatment of various diseases |
| 09/13/2001 | WO2001065911A2 Improved poloxamer and poloxamine compositions for nucleic acid delivery |
| 09/13/2001 | WO2001029178A3 Epo primary response gene 1, eprg1 |
| 09/13/2001 | WO2001028993A3 Tyrosine kinase inhibitors |
| 09/13/2001 | WO2001017536A3 Novel autogenous vaccines used to obtain an immune tolerance |
| 09/13/2001 | WO2001015733A3 Compositions for treating autoimmune disease containing a compounds which regulates icam-lfa-1 interaction and a compounds which regulates cd40-cd40 ligand interaction |
| 09/13/2001 | WO2001003744A3 Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of the c, d or v genes |
| 09/13/2001 | WO2000063370A3 Nucleic acids coding for novel truncated cart proteins, corresponding truncated cart polypeptides and their use for therapeutic and diagnostic purposes |
| 09/13/2001 | WO2000043790A9 Compositions and methods for the diagnosis and treatment of tumor |
| 09/13/2001 | WO2000040701A9 Non-myeloablative tolerogenic treatment |
| 09/13/2001 | WO2000034780A8 METHODS AND COMPOSITIONS USEFUL FOR TARGETING ACTIVATED VITRONECTIN RECEPTOR αvβ¿3? |
| 09/13/2001 | WO1997042968A3 Administration of histamine for therapeutic purposes |
| 09/13/2001 | WO1996030521A3 Infectious dna clone of the tick-borne encephalitis (tbe) virus; recombinant vaccine derived from the said clone and production of the said vaccine; and a pharmaceutical product containing a replicable nucleic acid |
| 09/13/2001 | WO1995021922A3 Non-a, non-b, non-c, non-d, non-e hepatitis reagents and methods for their use |
| 09/13/2001 | US20010021517 An isolated nucleic acid molecule that hybridizes under stringent hybridization conditions with macrophase migration inhibiatory factor (MIF) gene selected from dirofilaria immitis MIF gene and Onchocerca volvulus MIF gene |
| 09/13/2001 | US20010021516 An isolated nucleic acid molecule comprising a polynucleotide having nucleotide sequence atleast 95% identical to a sequence selected from a nucleotide sequence encoding a TRID polypeptide having specific amino acid sequence |
| 09/13/2001 | US20010021507 Renal nuclear matrix protein able to differentiate cancerous renal cell from normal renal cells; useful for diagnosis and producing treatment for cell proliferative disorders of the kidney |
| 09/13/2001 | US20010021393 Antibodies from eggs immunized with urease of Helicobacter |
| 09/13/2001 | US20010021386 Salmonella vaccine |
| 09/13/2001 | US20010021385 Human papillomavirus vaccine with disassembled and reassembled virus-like particles |
| 09/13/2001 | US20010021384 Administering vaccine |
| 09/13/2001 | US20010021383 Antibodies for diagnosis, therapy |
| 09/13/2001 | DE19963840A1 Zusammensetzung zum Vorbeugen und Behandeln von allergischen Erkrankungen A composition for preventing and treating allergic diseases |
| 09/13/2001 | CA2799545A1 Adenovirus formulations |
| 09/13/2001 | CA2402602A1 Polynucleotides which are of nature b2/d+ a- and which are isolated from e. coli, and biological uses of these polynucleotides and of their polypeptides |
| 09/13/2001 | CA2402302A1 Production of foreign polypeptides in plants as viral coat protein fusions |
| 09/13/2001 | CA2402081A1 A compound that selectively binds to cd123 and use thereof to kill hematologic cancer progenitor cells |
| 09/13/2001 | CA2401549A1 G-protein coupled receptor related polypeptides |
| 09/13/2001 | CA2401327A1 Nucleic acid formulations comprising poly-amino acids for gene delivery and methods of use |
| 09/13/2001 | CA2401323A1 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases |
| 09/13/2001 | CA2401239A1 Improved poloxamer and poloxamine compositions for nucleic acid delivery |
| 09/13/2001 | CA2400628A1 Use of tgf-beta antagonists to treat or to prevent loss of renal function |
| 09/13/2001 | CA2400504A1 Composition for the treatment of heart failure |
| 09/12/2001 | EP1132466A1 Chicken anaemia viruses of low pathogenicity |
| 09/12/2001 | EP1132398A2 DNA sequence encoding the specific and antigenic outer membrane protein of salmonella typhi |
| 09/12/2001 | EP1132097A2 Cellular and serum protein anchors and conjugates |
| 09/12/2001 | EP1131633A2 Hiv-specific t-cell induction |
| 09/12/2001 | EP1131461A1 N-terminally truncated her-2/neu protein as a cancer prognostic indicator |
| 09/12/2001 | EP1131432A2 Cell surface receptor antigen vaccines |
| 09/12/2001 | EP1131428A2 Immunoglobulin superfamily proteins |
| 09/12/2001 | EP1131426A2 Mage-10 or mage-8 derived hla-a2.1-binding oligopeptides |
| 09/12/2001 | EP1131425A2 Inflammation-associated genes |
| 09/12/2001 | EP1131414A1 Stable, attenuated rabies virus mutants and live vaccines thereof |
| 09/12/2001 | EP1131358A1 Humanized antibody specific for surface antigen pre-s1 of hbv and preparation method thereof |
| 09/12/2001 | EP1131357A1 Humanized antibody specific for human 4-1bb and pharmaceutical composition comprising same |
| 09/12/2001 | EP1131356A1 Method for inhibiting macrophage infiltration using monoclonal anti-alpha-d-antibodies |
| 09/12/2001 | EP1131354A1 Contraceptive antibody vaccines |
| 09/12/2001 | EP1131352A2 Rantes-derived peptides with anti-hiv activity |
| 09/12/2001 | EP1131350A1 Egf-like nucleic acids and polypeptides and uses thereof |
| 09/12/2001 | EP1131347A2 Product |
| 09/12/2001 | EP1131346A1 Heliobacter pylori antigen |
| 09/12/2001 | EP1131345A1 Synthetic polypeptides corresponding to the hepatitis c virus (hcv) and applications |
| 09/12/2001 | EP1131338A1 Method for the production of purified invasin protein and use thereof |
| 09/12/2001 | EP1131106A1 Compositions and methods for producing vascular occlusion |
| 09/12/2001 | EP1131099A2 Noninvasive vascular therapy |
| 09/12/2001 | EP1131098A1 Cd25 binding molecules for use in the treatment of manifestations of rejection in transplantation |
| 09/12/2001 | EP1131097A1 Anti-icam-r antibody-induced apoptosis |
| 09/12/2001 | EP1131096A1 Chimeric anti-cd20 antibody treatment of patients receiving bmt or pbsc transplants |
| 09/12/2001 | EP1131095A1 Method of diagnosing, monitoring, staging, imaging and treating prostate cancer |
| 09/12/2001 | EP1131094A1 Multivalent t.d. polio vaccine against at least diphtheria, poliomyelitis and tetanus |
| 09/12/2001 | EP1131093A1 Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody |
| 09/12/2001 | EP1131092A1 Intradermal avian immunization with inactivated vaccines |
| 09/12/2001 | EP1131085A2 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration |
| 09/12/2001 | EP1131084A1 Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists |
| 09/12/2001 | EP0704056B1 Leukocyte adhesion assay |